sCXCL16在成人原发免疫性血小板减少症中的表达水平及临床意义

doi:10.3969/j.issn.1671-2587.2020.04.020

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (4): 420-425.DOI: 10.3969/j.issn.1671-2587.2020.04.020

sCXCL16在成人原发免疫性血小板减少症中的表达水平及临床意义

阳梅, 罗玉勤, 何川

610000 四川大学华西医院血液内科

收稿日期:2019-04-20 出版日期:2020-08-20 发布日期:2020-08-12
通讯作者: 何川, 男, 副主任医师, 博士, 主要从事血液疾病诊治工作, （E-mail）chuanhhx@163.com。
作者简介:阳梅（1986-）, 女, 四川成都人, 主治医师, 学士, 主要从事血液疾病诊治工作, （E-mail）yangmei6819@163.com。
基金资助:
*本课题受四川省教育厅科研计划项目（No.18ZA0201）资助

Expression Level and Clinical Significance of sCXCL16 in Adult Primary Immune Thrombocytopenia

YANG Mei, LUO Yu-qin, HE Chuan

Department of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan 610000

Received:2019-04-20 Online:2020-08-20 Published:2020-08-12

摘要/Abstract

摘要： 目的探讨sCXCL16在成人原发免疫性血小板减少症（ITP）血浆中的表达水平及临床意义。方法选取2016年12月-2018年12月在我院门诊就诊的ITP患者, 包括活跃期ITP患者46例, 缓解期ITP患者42例, 同时选取同期我院体检的正常人群40例作为正常对照组。酶联免疫吸附试验（ELISA）检测血浆sCXCL16的表达水平, 并检测血液中血小板（PLT）含量, 淋巴细胞亚群中CXCR6比例, 外周血单核细胞CXCL16和CXCR6的mRNA表达水平, 以及分析血浆sCXCL16与病程、有无出血及PLT之间的相关性。结果活跃期ITP患者血浆sCXCL16水平明显高于正常对照组和缓解期ITP患者（P<0.05）, 而血液PLT含量明显低于正常对照组和缓解期ITP患者（P<0.05）。活跃期ITP患者CXCR6在CD4⁺T细胞、CD8⁺T细胞、B细胞中的比例与正常对照组、缓解期ITP患者相比明显增加（P<0.05）。活跃期ITP患者外周血单核细胞CXCL16 mRNA、CXCR6 mRNA表达明显高于正常对照组、缓解期ITP组（P<0.05）。活跃期ITP患者血浆sCXCL16与病程之间无相关性（r= -0.032, P=0.894）, 与PLT含量之间也无相关性（r=0.034, P=0.883）, 但活跃期ITP患者血浆sCXCL16与有无出血之间存在正相关（r=0.532, P=0.025）;缓解期ITP患者及正常对照组血浆sCXCL16与病程、有无出血及PLT无相关性（P>0.05）。结论血浆sCXCL16可能通过调控CXCR6在淋巴细胞亚群中的比例, 从而参与ITP的发病机制, 其可以作为判断ITP治疗效果的生物标志。

关键词: sCXCL16, 血小板减少症, 淋巴细胞, 血小板

Abstract: Objective To identify the expression level and clinical significance of plasma sCXCL16 in adult primary immune thrombocytopenia (ITP). Methods From December 2016 to December 2018, patients diagnosed with ITP at our hospital outpatient clinic were selected, including 46 active ITP, 42 ITP in remission and 40 health control group. The expression level of plasma sCXCL16 was detected by enzyme-linked immunosorbent assays (ELISA), and platelet (PLT) count, proportion of CXCR6 expression on lymphocyte subsets, CXCL16 and CXCR6 mRNA expression levels in peripheral blood mononuclear cells(PMBC) were detected respectively. Then, correlation of plasma sCXCL16 with disease course, bleeding and PLT were analyzed. Results Plasma sCXCL16 levels in active ITP patients were significantly higher than those in control group（P<0.05）and of patients in remission（P<0.05）, while PLT count in active ITP patients was significantly lower than that in the control group（P<0.05）and of patients in remission（P<0.05）. The proportion of CXCR6 expressed on CD4+ T cells, CD8⁺ T cells, and B cells in active ITP patients was significantly higher than that in control group and of patients in remission (P<0.05). PMBC CXCL16 mRNA and CXCR6 mRNA levels in active ITP patients were higher than those in control group and of patients in remission（P<0.05）. Plasma sCXCL16 in active ITP patients was not associated with disease course（r=-0.032, P=0.894）, nor did with PLT count（r=0.034, P=0.883）, while plasma sCXCL16 in active ITP patients was positively correlated with bleeding（r=0.532, P=0.025）; There was no correlation between plasma sCXCL16 levels and disease course, bleeding and PLT in patients with remission and normal control group（P>0.05）. Conclusion Plasma sCXCL16 levels might be involved in the pathogenesis of ITP by regulating the proportion of CXCR6 in lymphocyte subsets. It can be used as a biomarker to assess efficacy of ITP treatments.

Key words: sCXCL16, Thrombocytopenia, Lymphocyte, Platelet

中图分类号:

R558⁺.2

阳梅, 罗玉勤, 何川. sCXCL16在成人原发免疫性血小板减少症中的表达水平及临床意义[J]. 临床输血与检验, 2020, 22(4): 420-425.

YANG Mei, LUO Yu-qin, HE Chuan. Expression Level and Clinical Significance of sCXCL16 in Adult Primary Immune Thrombocytopenia[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(4): 420-425.

参考文献

[1] 郭宏岗, 沈建良.原发免疫性血小板减少症发病机制的研究进展[J].山东医药, 2016, 56(11):96-99.
[2] Zufferey A, Kapur R, Semple J.Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)[J].J Clin Med, 2017, 6(2):16.
[3] 温顺祝, 傅红春, 李晓明.原发性免疫性血小板减少症研究进展[J].西南国防医药, 2016, 26(7):821-823.
[4] Min Y N, Wang C Y, Li X X, et al.Participation of B-cell-activating factor receptors in the pathogenesis of immune thrombocytopenia[J].J Thromb Haemost, 2016, 14(3):559-571.
[5] El-Rashedi F H, El-Hawy M A, Helwa M A, et al.Study of CD4+, CD8+, and natural killer cells(CD16+, CD56+) in children with immune thrombocytopenic Purpura[J].Hematol Stem Cell Ther, 2017, 10(1):8-14.
[6] Takahashi N, Saitoh T, Gotoh N, et al.The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP[J].BMC Immunol, 2017, 18(1):1-11.
[7] Dreymueller D, Goetzenich A, Emontzpohl C, et al.The perioperative time course and clinical significance of the chemokine CXCL16 in patients undergoing cardiac surgery[J].J Cell Mol Med, 2016, 20(1):104-115.
[8] Hao Y T, Li Y, Li H Y, et al.Increased plasma sCXCL16 levels may have a relationship with Th1/Th2 imbalance in primary immune thrombocytopenia[J].Cytokine, 2017, 99:124-131.
[9] Tang YY, Wei YF, Ye Z M, et al.Th1, Th17, CXCL16 and homocysteine elevated after intracranial and cervical stent implantation[J].Int J Neurosci, 2017, 127(8):701-708.
[10] Ke CW, Ren YC, Lv L, et al.Association between CXCL16/CXCR6 expression and the clinicopathological features of patients with non-small cell lung cancer[J].Oncol Lett, 2017, 13(6):4661-4668.
[11] 中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志, 2016, 37(2):89-93.
[12] 陈玙, 王梅芳, 程芳芳, 等.老年原发免疫性血小板减少症患者临床特征及预后分析[J].首都医科大学学报, 2018, 39(2):277-281.
[13] 郭莹, 瞿文, 王一浩, 等.共刺激信号分子对免疫性血小板减少症患者B淋巴细胞免疫功能的影响[J].中国实验血液学杂志, 2016, 24(4):1110-1115.
[14] 陈燕, 邢宏运, 李晓明, 等.Fas/FasL在原发免疫性血小板减少症发病机制中的作用研究[J].重庆医学, 2016, 45(20):2795-2797.
[15] Gruber H, Marrero E, Ingram J, et al.The chemokine, CXCL16, and its receptor, CXCR6, are constitutively expressed in human annulus fibrosus and expression of CXCL16 is up-regulated by exposure to IL-1ß in vitro[J].Biotech Histochem, 2017, 92(1):7-14.
[16] 戴昕, 李文倩, 李建平, 等.血浆HMGB1、IFN-γ、IL-4和CD4~+T细胞表面TLR4的表达在免疫性血小板减少症患者中的意义[J].中国实验血液学杂志, 2016, 24(6):1837-1841.
[17] Takiguchi G, Nishita M, Kurita K, et al.Wnt5a-Ror2 signaling in mesenchymal stem cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 axis[J].Cancer Sci, 2016, 107(3):290-297.
[18] Cho SW, Kim YA, Sun H J, et al.CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma[J].Endocr-Relat Cancer, 2016, 23(2):113-124.
[19] Wu JB, He Y, Luo YN, et al.MiR-145-5p inhibits proliferation and inflammatory responses of RMC through regulating AKT/GSK pathway by targeting CXCL16[J].J Cell Physiol, 2018, 233(4):3648-3659.
[20] Chapin J, Lee CS, Zhang HY, et al.Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia[J].Am J Hematol, 2016, 91(9):907-911.

sCXCL16在成人原发免疫性血小板减少症中的表达水平及临床意义

Expression Level and Clinical Significance of sCXCL16 in Adult Primary Immune Thrombocytopenia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	贾彦军, 赵续影, 魏珍珍. 白藜芦醇对小鼠血小板氧化应激和衰老指标及储存时间的影响^*[J]. 临床输血与检验, 2021, 23(2): 137-141.
[2]	林放, 周谋, 单桂秋, 李艳辉, 李文丹. 不同来源复水液对冻干PRP活化和释放生长因子影响的比较^*[J]. 临床输血与检验, 2021, 23(2): 142-145.
[3]	赵娜娜, 王超, 金惠新, 赵阳, 吕蓉. 合肥地区无偿献血人群CD36抗原缺失的调查^*[J]. 临床输血与检验, 2021, 23(2): 152-155.
[4]	王慧茹, 刘会兰. 非血缘脐血移植术后患者输血情况相关影响因素分析^*[J]. 临床输血与检验, 2021, 23(2): 162-166.
[5]	郑静娴, 李晓辉, 孙洪强. 儿童免疫性血小板减少症的临床观察及抗核抗体在其中作用的研究[J]. 临床输血与检验, 2021, 23(2): 231-235.
[6]	冯子阳, 查占山, 周载鑫, 唐河山, 余咏潮, 钱宝华. 一例血浆置换在马凡综合征患者术后并发血栓性血小板减少性紫癜治疗中的应用[J]. 临床输血与检验, 2021, 23(2): 242-245.
[7]	张嘉英, 樊斌, 朱立国, 汪德清, 李捷. 核黄素光化学法处理对全血中淋巴细胞功能的影响[J]. 临床输血与检验, 2020, 22(6): 599-602.
[8]	王瑞含, 范金波, 周国均, 王飞, 刘久波. PRP治疗膝骨关节炎的临床应用研究进展[J]. 临床输血与检验, 2020, 22(6): 659-663.
[9]	周博, 田茂生, 马晨, 任晓朦, 朱传福. 淄博地区血小板捐献者HLA-A,B和HPA1-17分型资料库的建立^*[J]. 临床输血与检验, 2020, 22(5): 510-514.
[10]	成枫, 许宏, 肖淑欣, 赵洪国. HPA-1-6/17基因多态性与青岛市血小板减少症遗传易感性的关系分析[J]. 临床输血与检验, 2020, 22(5): 521-526.
[11]	张媛媛, 潘健, 应美爱, 王敏, 王慧茹. ABO血型次侧不相合肾移植术后发生过客淋巴细胞综合征1例诊断与输血^*[J]. 临床输血与检验, 2020, 22(5): 542-544.
[12]	谢毓滨, 邹彬彬, 陈东, 阳智芬, 谭智文, 王清, 旷开其, 晏永和. 新冠恢复期血浆拟捐献者健康评估及抗体水平分析[J]. 临床输血与检验, 2020, 22(4): 343-348.
[13]	强萍, 薛磊, 汪敏, 许汉英, 刘欣, 朱薇波, 杨林, 王兴兵. 成功救治2例CAR-T细胞治疗后伴严重细胞因子风暴和相关性脑病伴文献复习[J]. 临床输血与检验, 2020, 22(4): 413-419.
[14]	苏蔓, 李茵, 赵倩, 胡光磊, 王振雷, 何路军. 石家庄地区已知HLA型别单采血小板捐献者基因资料库库容评价^*[J]. 临床输血与检验, 2020, 22(3): 290-294.
[15]	王皓, 郭兴莹, 张志波, 张新萍, 冀春红, 黄象艳. HLA与HPA配型不合导致血小板输注无效1例[J]. 临床输血与检验, 2020, 22(3): 334-336.